Amarin Corp Plc (AMRN)

[Atom0aks]

What controversy? The only 'controversy' that I am aware of is that I think that hundreds of deaths and thousands of events in 3 months is a lot, while you think that it's "very, very little".

This controversy,

In an editorial in BMJ, Gigerenzer et al1 chastised researchers who committed “sins” against transparent reporting, such as presenting relative risk (which inflates the appearance of interventions) without presenting absolute risk (which provides a more appropriate assessment of the benefit of an intervention).

A 28% reduction in risk of coronary-related death appears impressive to unsophisticated readers, but this form of data presentation is what Gigerenzer et al. called “incomplete and misleading risk information”.

The 28% effect reported by Wise, as well as in the abstract of the publication by Vallejo-Vaz et al., is referred to as relative risk reduction, which, when presented in isolation, is an amplification of the appearance of a benefit to a treated versus untreated group. The actual difference in rates of coronary death to the population (the absolute risk) reported by Vallejo-Vaz et al. were 9% in placebo and 6.7% in treated individuals. Therefore, the clinically relevant difference in the rate of coronary death between treated and untreated groups was only 2.3%, not 28%.

Finally,

Thus, both Vallejo-Vaz et al. and Wise have misinformed readers by focusing solely on the more dramatic, but misleading, relative risk statistic.

Source: https://www.bmj.com/content/358/bmj.j4171/rr

Oh and speaking of statins, NNT for Vascepa is 21, while:

Atorvastatin (Lipitor®) is 45

Evolocumab(Repatha®) is 67

Rosuvastatin (Crestor) is 20

Source: https://www.ahajournals.org/doi/full/10.1161/CIRCOUTCOMES.109.848473?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

But this discussion of NNT is outside the scope of why I provided the original article.